Piperacillin-tazobactam combination product

ApprovedSmall molecule

Piperacillin-tazobactam combination product is one of 115 small molecule programs targeting Neutropenia. It is currently in Approved.

Indications

Total Trials

Active Trials

114

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeutropeniaActive, not recruiting

MortalityActive, not recruiting

CholecystitisActive, not recruiting

Cystic FibrosisActive, not recruiting

NeutropeniaPreclinical

Active, not recruiting

MortalityApproved

Active, not recruiting

CholecystitisPhase 3

Active, not recruiting

Cystic FibrosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

Piperacillin-tazobactam combination product

TThe University of Queensland

Approved

2 2

Onglyza

AstraZeneca

Preclinical

2 3

Calciferol

Alnylam Pharmaceuticals

Preclinical

1 4

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

3 5

Actimmune

HHorizon Therapeutics Ireland DAC

Preclinical

2 6

Proair HFA

GGlaxo Dba Glaxosmithkline

Preclinical

2 7

Aztreonam Lysine

Gilead

Preclinical

5 8

Capromorelin

UUniversity of Aarhus

Preclinical

1 9

Feosol

AAuerbach Hematology Oncology Associates P C

Preclinical

1 10

Serevent

GGlaxo Dba Glaxosmithkline

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cystic Fibrosis2 trials

Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis

Terminated·WWest Virginia University·Phase 4·NCT01694069·6 enrolled

LC-MS/MS Based Method Development for the Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients

Terminated·UUniversity Ghent·N/A·NCT02840136·40 enrolled

Antibiotic1 trial

AbioKin - Antibiotic Kinetics

Completed·GGruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva··NCT02609646·1,500 enrolled

Cholecystitis1 trial

Piperacllin Versus Placebo in Patients Undergoing Surgery for Acute Cholecystitis

Completed·KKarolinska Institutet·Phase 3·NCT02619149·100 enrolled

Neutropenia1 trial

Piperacillin/Tazobactam for Empirical Therapy of Febrile Neutropenia

Completed·—·N/A·NCT01714570·123 enrolled

Mortality1 trial

Trial of Meropenem Versus Piperacillin-Tazobactam on Mortality and Clinial Response

Completed·TThe University of Queensland·Phase 4·NCT02437045·100 enrolled

2 more indications

Hematopoietic Stem Cell Transplantation1 trial

Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation

Unknown status·—·N/A·NCT01714557·150 enrolled

Treatment1 trial

RCT Meropenem vs Piperacillin-Tazobactam for Definitive Treatment of BSI's Due to Ceftriaxone Non-susceptible Escherichia Coli and Klebsiella Spp.

Terminated·TThe University of Queensland·Phase 4·NCT02176122·391 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Piperacillin-tazobactam combination product. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Piperacillin-tazobactam combination product compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Piperacillin-tazobactam combination product. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The University of Queensland company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TThe University of Queensland

Piperacillin-tazobactam combination product

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cystic Fibrosis2 trials

Antibiotic1 trial

Cholecystitis1 trial

Neutropenia1 trial

Mortality1 trial

Hematopoietic Stem Cell Transplantation1 trial

Treatment1 trial

References

Drug Info

Quick Facts

Related News